View in EDS

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.

Saved in:
Bibliographic Details
Title: Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.
Authors: Cascone T; Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: tcascone@mdanderson.org., Sacks RL; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Subbiah IM; Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Drobnitzky N; Department of Oncology, Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK., Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Hess KR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA., Amini B; Department of Musculoskeletal Radiology, The University of Texas MD Anderson Cancer Center, Houston, USA., Bhatt T; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Fu S; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Naing A; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Karp D; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Falchook GS; Sarah Cannon Research Institute at HealthONE, Denver, USA., Conley AP; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Sherman SI; Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA., Ryan AJ; Department of Oncology, Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK., Heymach JV; Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA., Subbiah V; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: vsubbiah@mdanderson.org.
Source: ESMO open [ESMO Open] 2021 Apr; Vol. 6 (2), pp. 100079. Date of Electronic Publication: 2021 Mar 12.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33721621
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Cascone+T%22">Cascone T</searchLink>; Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: tcascone@mdanderson.org.<br /><searchLink fieldCode="AU" term="%22Sacks+RL%22">Sacks RL</searchLink>; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Subbiah+IM%22">Subbiah IM</searchLink>; Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Drobnitzky+N%22">Drobnitzky N</searchLink>; Department of Oncology, Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Piha-Paul+SA%22">Piha-Paul SA</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Hong+DS%22">Hong DS</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Hess+KR%22">Hess KR</searchLink>; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Amini+B%22">Amini B</searchLink>; Department of Musculoskeletal Radiology, The University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Bhatt+T%22">Bhatt T</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Fu+S%22">Fu S</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Naing+A%22">Naing A</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Janku+F%22">Janku F</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Karp+D%22">Karp D</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Falchook+GS%22">Falchook GS</searchLink>; Sarah Cannon Research Institute at HealthONE, Denver, USA.<br /><searchLink fieldCode="AU" term="%22Conley+AP%22">Conley AP</searchLink>; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Sherman+SI%22">Sherman SI</searchLink>; Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Meric-Bernstam+F%22">Meric-Bernstam F</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Ryan+AJ%22">Ryan AJ</searchLink>; Department of Oncology, Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Heymach+JV%22">Heymach JV</searchLink>; Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Subbiah+V%22">Subbiah V</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: vsubbiah@mdanderson.org.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101690685%22">ESMO open</searchLink> [ESMO Open] 2021 Apr; Vol. 6 (2), pp. 100079. <i>Date of Electronic Publication: </i>2021 Mar 12.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101690685 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2059-7029 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220597029%22">20597029 </searchLink><i>NLM ISO Abbreviation: </i>ESMO Open <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33721621
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.esmoop.2021.100079
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 100079
    Titles:
      – TitleFull: Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Cascone T
      – PersonEntity:
          Name:
            NameFull: Sacks RL
      – PersonEntity:
          Name:
            NameFull: Subbiah IM
      – PersonEntity:
          Name:
            NameFull: Drobnitzky N
      – PersonEntity:
          Name:
            NameFull: Piha-Paul SA
      – PersonEntity:
          Name:
            NameFull: Hong DS
      – PersonEntity:
          Name:
            NameFull: Hess KR
      – PersonEntity:
          Name:
            NameFull: Amini B
      – PersonEntity:
          Name:
            NameFull: Bhatt T
      – PersonEntity:
          Name:
            NameFull: Fu S
      – PersonEntity:
          Name:
            NameFull: Naing A
      – PersonEntity:
          Name:
            NameFull: Janku F
      – PersonEntity:
          Name:
            NameFull: Karp D
      – PersonEntity:
          Name:
            NameFull: Falchook GS
      – PersonEntity:
          Name:
            NameFull: Conley AP
      – PersonEntity:
          Name:
            NameFull: Sherman SI
      – PersonEntity:
          Name:
            NameFull: Meric-Bernstam F
      – PersonEntity:
          Name:
            NameFull: Ryan AJ
      – PersonEntity:
          Name:
            NameFull: Heymach JV
      – PersonEntity:
          Name:
            NameFull: Subbiah V
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2021 Apr
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 2059-7029
          Numbering:
            – Type: volume
              Value: 6
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: ESMO open
              Type: main
ResultId 1